Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Other Non-Current Liabilities (2016 - 2025)

Gsk has reported Other Non-Current Liabilities over the past 10 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $1.4 billion for Q4 2025, down 3.62% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (down 3.62% YoY), and the annual figure for FY2025 was $1.4 billion, down 3.62%.
  • Other Non-Current Liabilities for Q4 2025 was $1.4 billion at Gsk, down from $1.4 billion in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for GLAXF hit a ceiling of $1.4 billion in Q4 2024 and a floor of $1.1 billion in Q4 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $1.4 billion (2025), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Other Non-Current Liabilities: dropped 15.07% in 2022 and later surged 30.3% in 2023.
  • Gsk's Other Non-Current Liabilities stood at $1.2 billion in 2021, then dropped by 15.07% to $1.1 billion in 2022, then surged by 30.3% to $1.4 billion in 2023, then rose by 2.76% to $1.4 billion in 2024, then decreased by 3.62% to $1.4 billion in 2025.
  • The last three reported values for Other Non-Current Liabilities were $1.4 billion (Q4 2025), $1.4 billion (Q4 2024), and $1.4 billion (Q4 2023) per Business Quant data.